DE69717263D1 - Zubereitung mit verzögerter freisetzung und deren herstellung - Google Patents

Zubereitung mit verzögerter freisetzung und deren herstellung

Info

Publication number
DE69717263D1
DE69717263D1 DE69717263T DE69717263T DE69717263D1 DE 69717263 D1 DE69717263 D1 DE 69717263D1 DE 69717263 T DE69717263 T DE 69717263T DE 69717263 T DE69717263 T DE 69717263T DE 69717263 D1 DE69717263 D1 DE 69717263D1
Authority
DE
Germany
Prior art keywords
production
preparation
delayed release
sustained
dispersing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69717263T
Other languages
English (en)
Other versions
DE69717263T2 (de
Inventor
Shigeyuki Takada
Tomofumi Kurokawa
Susumu Iwasa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of DE69717263D1 publication Critical patent/DE69717263D1/de
Application granted granted Critical
Publication of DE69717263T2 publication Critical patent/DE69717263T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
DE69717263T 1996-03-28 1997-03-27 Zubereitung mit verzögerter freisetzung und deren herstellung Expired - Lifetime DE69717263T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7301696 1996-03-28
PCT/JP1997/001041 WO1997035563A2 (en) 1996-03-28 1997-03-27 Sustained-release preparation and its production

Publications (2)

Publication Number Publication Date
DE69717263D1 true DE69717263D1 (de) 2003-01-02
DE69717263T2 DE69717263T2 (de) 2003-07-24

Family

ID=13506129

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69717263T Expired - Lifetime DE69717263T2 (de) 1996-03-28 1997-03-27 Zubereitung mit verzögerter freisetzung und deren herstellung

Country Status (8)

Country Link
US (2) US6190702B1 (de)
EP (1) EP0889722B1 (de)
AT (1) ATE227980T1 (de)
AU (1) AU2043297A (de)
CA (1) CA2241322C (de)
DE (1) DE69717263T2 (de)
DK (1) DK0889722T3 (de)
WO (1) WO1997035563A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000500744A (ja) 1995-11-09 2000-01-25 マイクロバイオロジカル リサーチ オーソリティー ワクチン接種および遺伝子治療のためのマイクロカプセル化ｄｎａ
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US6287587B2 (en) 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
US6740634B1 (en) 1998-01-16 2004-05-25 Takeda Chemical Industries, Ltd. Sustained release compositions, process for producing the same and utilization thereof
EP1049458B1 (de) * 1998-01-21 2003-03-26 Takeda Chemical Industries, Ltd. Verfahren zur gerfriertrocknung von präparaten mit verzörgerter wirkstoffabgabe
AU744354B2 (en) 1998-03-20 2002-02-21 Takeda Chemical Industries Ltd. Sustained-release preparation of physiologically active polypeptide and production thereof
GB9810236D0 (en) * 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
WO2001051032A2 (en) * 2000-01-14 2001-07-19 Brown University Research Foundation Micronized freeze-dried particles
US7029700B2 (en) 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
EP1265630B1 (de) 2000-03-24 2006-06-07 Genentech, Inc. Verwendung von insulin zur behandlung von knorpelkrankheiten
US20080233165A1 (en) * 2000-08-07 2008-09-25 Biolok International, Inc. Time release calcium sulfate and growth factor matrix for bone augmentation
US7488761B2 (en) * 2000-08-07 2009-02-10 Orthogen Llc Polymer containing calcium sulfate particles for bone augmentation
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
CA2680475A1 (en) 2000-12-28 2002-07-11 Shigeyuki Takada Sustained-release preparation
JP2002265383A (ja) * 2001-03-14 2002-09-18 Mitsubishi Pharma Corp インターフェロンα注射用液状製剤
WO2002078673A1 (fr) * 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Procede de production d'un medicament sous forme de granules fins
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US6887897B2 (en) 2001-07-31 2005-05-03 Mission Pharmacal Company Calcium glutarate supplement and phosphorus binder
CA2471521C (en) * 2001-12-26 2010-11-02 Takeda Chemical Industries, Ltd. Novel microsphere and method for production thereof
HUE034378T2 (en) 2002-10-16 2018-02-28 Purdue Pharma Lp Cell-associated CA 125 / O722P binding antibodies and methods of use
AU2003277446A1 (en) 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US20060110423A1 (en) * 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
MXPA06011924A (es) * 2004-04-15 2007-06-11 Alkermes Inc Dispositivo de liberacion continua base polimeros.
US8075910B2 (en) * 2004-05-20 2011-12-13 Pbm Pharmaceuticals, Inc. Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
DE102005017777A1 (de) * 2005-04-13 2006-10-19 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Partikelsuspensionen
EP1868574B1 (de) * 2005-04-13 2010-01-06 Abbott GmbH & Co. KG Verfahren zur schonenden herstellung hochfeiner partikelsuspensionen und hochfeiner partikel sowie deren verwendung
ES2422864T3 (es) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Sistemas de liberación osmótica y unidades de pistón
JP2010522196A (ja) * 2007-03-22 2010-07-01 アルカームズ，インコーポレイテッド コアセルベーション工程
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
WO2008157540A1 (en) * 2007-06-20 2008-12-24 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
EP2044934A1 (de) * 2007-10-01 2009-04-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dispersion von Poloxamer-Proteinpartikeln, Herstellungsmethoden und Verwendung davon
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
KR101760953B1 (ko) * 2008-09-04 2017-07-24 아밀린 파마슈티칼스, 엘엘씨. 비-수성 담체를 이용한 서방성 제형물
EP3210474B1 (de) 2008-09-17 2020-11-18 Chiasma, Inc. Pharmazeutische zusammensetzungen mit polypeptiden und zugehörige abgabeverfahren
EP3323423B1 (de) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA41462A (fr) 2015-02-03 2021-05-12 Chiasma Inc Méthode de traitement de maladies
EP3302354B1 (de) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Systeme zum einsetzen eines implantats
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
EP4218738A1 (de) 2017-02-24 2023-08-02 The Regents of The University of California Partikeltropfenstrukturen und verfahren zur herstellung und verwendung davon
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
US4774091A (en) 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
JP3116311B2 (ja) 1990-06-13 2000-12-11 エーザイ株式会社 マイクロスフィアの製法
NO302481B1 (no) 1990-10-16 1998-03-09 Takeda Chemical Industries Ltd Polymer for et preparat med forlenget frigjöring, samt preparat med forlenget frigjöring
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
EP0674506B1 (de) 1992-12-02 2000-08-23 Alkermes Controlled Therapeutics, Inc. Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
PT686045E (pt) 1993-02-23 2001-04-30 Genentech Inc Estabilizacao por excipientes de polipeptidos tratados com solventes organicos
NZ260909A (en) 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
CA2172508C (en) 1993-10-22 2005-08-23 Jeffrey L. Cleland Method for preparing microspheres comprising a fluidized bed drying step
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
TW448055B (en) * 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
EP0765660A3 (de) * 1995-09-28 1998-09-23 Takeda Chemical Industries, Ltd. Mikrokapseln enthaltend 2-Piperazinon-1-essigsäure Verbindungen

Also Published As

Publication number Publication date
DK0889722T3 (da) 2003-02-10
WO1997035563A2 (en) 1997-10-02
DE69717263T2 (de) 2003-07-24
US20010006678A1 (en) 2001-07-05
EP0889722A2 (de) 1999-01-13
ATE227980T1 (de) 2002-12-15
US6190702B1 (en) 2001-02-20
EP0889722B1 (de) 2002-11-20
AU2043297A (en) 1997-10-17
CA2241322A1 (en) 1997-10-02
CA2241322C (en) 2009-01-13
WO1997035563A3 (en) 1997-11-20

Similar Documents

Publication Publication Date Title
DE69717263T2 (de) Zubereitung mit verzögerter freisetzung und deren herstellung
MX9102763A (es) Proceso para la preparacion de productos vegetales deshidratados y productos resultantes.
DE60106666D1 (de) Kontinuierlicher Prozess für die Herstellung von Mikrokapseln mit verzögerten Freisetzung von wasserlöslichen Peptiden
DE68903482T2 (de) Zement, verfahren zur herstellung dieses zements und verfahren zur herstellung von produkten mit diesem zement.
EP0813821A4 (de) Verarbeitetes fischfleisch, fischfleischmaterial davon und verfahren zur herstellung von verarbeiteten fischfleisch
HUP9600647A1 (en) Phosphono-monoester-nucleinic acids, process for producing them, and their use
ES2102388T3 (es) Polidextrosa modificada y procedimiento para su preparacion.
TR199800285T1 (xx) Katk�l� bir gofret yap�m� i�in i�lem.
PT709034E (pt) Processo para o fabrico de um agente de textura para produtos lacteos
MX25011A (es) Producto que contiene pectina y metodo para su produccion.
DE69015024T2 (de) Unter Feldeffekt-Emission arbeitende Schaltanordnung und deren Herstellungsverfahren.
GB2294045B (en) Novel sulfonate, process for producing the same, and bleach composition comprising the same
AU2503788A (en) Process for the production of biodegradable microcapsules of water-soluble peptides and proteins, and microcapsules obtained by this process
BG102623A (en) New derivatives of benzoylguanadine, methods for their preparation and application for the manufacture of medicamentous forms
FI971861A0 (fi) Puristuskoostumus, valmistusmenetelmä, puristusmenetelmä ja puristustuotteita
DE59009112D1 (de) Scheinwerfer, der in seiner Helligkeit stufenlos regelbar ist.
NO176808C (no) Fremgangsmåte for fremstilling av hydrolyserte vegetabilske proteiner.
PL325398A1 (en) Novel derivatives of carboxylic acids, their production and application
GB2264657B (en) Procedure for manufacturing decorative sheets for making nativity scenes,window-dressing,fishtank decorations and other applications
WO2000058298A3 (en) PROCESS FOR THE PREPARATION OF α-METHYLENELACTONES AND α-SUBSTITUTED HYDROCARBYLIDENE LACTONES
AU693483B2 (en) Base for sustained-release preparation, sustained-release preparation, and process for producing the preparation
MX9102624A (es) Composicion de shampoo acondicionador y proceso para su produccion.
ITRM920878A0 (it) Procedimento per ottenere statuine per presepi, immagini, statuine decorative e simili.
FR2686544B1 (fr) Plaque de matiere synthetique comportant des motifs decoratifs dans la masse et son procede de fabrication par extrusion et calaudage.
MX20250A (es) Metodo para obtener una solucion de la 25-ciclohexil avermectina b1 y producto obtenido mediante el mismo.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: TAKEDA PHARMACEUTICAL CO. LTD., OSAKA, JP